Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neural Transmission"
DOI: 10.1007/s00702-018-1964-3
Abstract: Rasagiline is a monoamine oxidase B inhibitor with demonstrated efficacy and safety in patients with Parkinson’s disease (PD). We recently conducted the first randomized, double-blind, placebo-controlled trial of rasagiline in Japanese patients with early PD… read more here.
Keywords: patients early; placebo rasagiline; rasagiline; japanese patients ... See more keywords